Article Text

Download PDFPDF
Systematic review
Current evidence for ART practice: the Cochrane of Cochranes on optimising outcomes
  1. Joyce C Harper1,2,
  2. Daniel R Brison3
  1. 1UCL Centre for PG & D, Institute for Women's Health, University College London, London, UK
  2. 2Centre for Reproductive and Genetic Health, London, UK
  3. 3Department of Reproductive Medicine, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK
  1. Correspondence to : Dr Joyce Harper, UCL Centre for PG&D, Institute for Womens Health, University College London, 86-96 Chenies Mews, London, WC1E 6HX; joyce.harper{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlPubMed


Assisted reproductive technology (ART) is a complex and expensive field of medicine. As such, new technology and new procedures are continually being developed with the aim of improving success rates. In the majority of cases, these are brought into clinical practice without sufficient research and development or scrutiny via randomised controlled trials (RCTs).1 Efficacy and safety issues should be considered before clinical application, including long-term follow-up of children.2 ,3

The issue with performing high-quality RCTs is that they are expensive to run and take several …

View Full Text


  • Competing interests DRB is a minor shareholder in Novocellus Ltd, a University of York spin-off company developing methods for diagnosing embryo health.